Organization | Scott and White Healthcare

Scott and White Healthcare Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Temple TX United States (1897)

Organization Overview

First Clinical Trial

1998

NCT00138294

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Scott and White Hospital & Clinic

Active Ingredients

Drugs in Phase 4 Trials (11)

aprepitant (Emend) (1 trial)

cortisone acetate (cortone) (1 trial)

epinephrine (levophed) (1 trial)

estradiol (progynon depot) (1 trial)

inactivated influenza vaccine (1 trial)

levobupivacaine (chirocaine) (1 trial)

lidocaine (xylocaine) (1 trial)

live attenuated influenza virus vaccine (Flumist) (1 trial)

norethindrone (2 trials)

ondansetron (zofran) (1 trial)

Drugs in Phase 2 Trials (3)

resimmune (2 trials)

sodium aluminosilicate (1 trial)

vorinostat (zolinza) (1 trial)

Drugs in Other Trials (4)

alteplase (Activase) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

frovatriptan (frova) (1 trial)

paricalcitol (zemplar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Clostridium Infections (Phase 2)

Diarrhea (Phase 2)

Hemorrhage (Phase 4)

Hip Injuries (Phase 4)

Infections (Phase 2)

Influenza, Human (Phase 4)

Leukemia, T-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Menorrhagia (Phase 4)

Metrorrhagia (Phase 4)

Migraine Disorders (Phase 4)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Postoperative Nausea and Vomiting (Phase 4)

Premenstrual Syndrome (Phase 4)

Sezary Syndrome (Phase 2)

Vomiting (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial APIs: 18